Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib

Owen A. O'Connor, MD, PhD, Leslie Popplewell, M.D., Jane N. Winter, M.D., RuiRong Yuan, MD, PhD, Anna Robeva, MS, Helene Cauwel, Quincy Chau, Michael Wang, MD

Blood (2010) 116 (21): 3963.

https://doi.org/10.1182/blood.V116.21.3963.3963

Published: 2010

Journal Articles

Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)

Francine M Foss, MD, Steven M Horwitz, MD, Lauren Pinter-Brown, MD, Andre Goy, MD, Barbara Pro, MD, Bertrand Coiffier, MD, PhD, Leslie Popplewell, M.D., Kerry Joanne Savage, MD, BSc, MSc, Andrei Shustov, MD, Jasmine M. Zain, MD, Tony Koutsoukos, Steven M. Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2010) 116 (21): 1762.

https://doi.org/10.1182/blood.V116.21.1762.1762

Published: 2010

Journal Articles

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Andrei Shustov, MD, Barbara Pro, MD, Christian Gisselbrecht, MD, Leslie Popplewell, M.D., Nancy L. Bartlett, MD, Mary Jo Lechowicz, MD, Jasmine M. Zain, MD, Faith Young, Richard R. Furman, MD, Steven M. Fruchtman, MD, Steven M Horwitz, MD, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 4882.

https://doi.org/10.1182/blood.V116.21.4882.4882

Published: 2010

Journal Articles

Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation

Mark Kirschbaum, MD, Anthony Selwyn Stein, M.D., Paul Frankel, Leslie Popplewell, M.D., Robert w Chen, Maria L Delioukina, MD, Ryotaro Nakamura, MD, David S. Snyder, MD, Cynthia Slape, Christopher Ruel, Joel Conrad, Auayporn Nademanee, M.D., Stephen Forman, MD

Blood (2010) 116 (21): 528.

https://doi.org/10.1182/blood.V116.21.528.528

Published: 2010

Journal Articles

Analysis of Risk Factors and Outcome for Extramedullary Relapses Post Allogeneic Stem Cell Transplantation for Myeloma.

Myo Htut, MD, Firoozeh Sahebi, M.D., George Somlo, MD, Pablo Parker, M.D., Chatchada Karanes, MD, Andy Dagis, Susan Hmwe, Tanya Paris, Joyce Murata-Collins, PhD, Leslie Popplewell, M.D., Joycelynne Palmer, PhD., Stephen Forman, M.D., Amrita Krishnan, M.D.

Blood (2010) 116 (21): 4562.

https://doi.org/10.1182/blood.V116.21.4562.4562

Published: 2010

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Mark Kirschbaum, MD, Leslie Popplewell, M.D., Maria L Delioukina, MD, Robert w Chen, Vinod Pullarkat, Paul Frankel, Joel Conrad, Joyce Hartshorn, Auayporn Nademanee, M.D., Stephen Forman, MD

Blood (2010) 116 (21): 3957.

https://doi.org/10.1182/blood.V116.21.3957.3957

Published: 2010

Journal Articles

Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period

Ari M. Vander Walde, M.D., M.P.H., Can-Lan Sun, Ph.D., Liton Francisco, B.S., Saro Armenian, D.O., M.P.H., Jennifer Berano Teh, M.D., F. Lennie Wong, Ph.D., Neal Kogut, M.D., Amrita Krishnan, M.D., Auayporn Nademanee, M.D., Leslie Popplewell, M.D., Anthony Selwyn Stein, M.D., Stephen J. Forman, M.D., Smita Bhatia

Blood (2010) 116 (21): 933.

https://doi.org/10.1182/blood.V116.21.933.933

Published: 2010

Journal Articles

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

Lester A. Laddaran, B.A., Can-Lan Sun, Ph.D., Ari M. VanderWalde, MD, MPH, Liton Francisco, B.S., Saro Armenian, D.O., M.P.H., Jennifer Berano Teh, M.D., F. Lennie Wong, Ph.D., Chatchada Karanes, MD, Neil Martin Kogut, MD, Amrita Krishnan, M.D., Auayporn Nademanee, M.D., Margaret O'Donnell, M.D., F.R.C.P.C., Pablo Parker, M.D., Leslie Popplewell, M.D., Anthony Selwyn Stein, M.D., Stephen J. Forman, M.D., Smita Bhatia

Blood (2010) 116 (21): 902.

https://doi.org/10.1182/blood.V116.21.902.902

Published: 2010

Journal Articles

High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous Peripheral Stem Cell Transplant (PSCT) In Patients with Multiple Myeloma. Results of a Phase II Prospective Study

Firoozeh Sahebi, M.D., Amrita Krishnan, M.D., Leonardo Farol, MD, Ji-Lian Cai, MD, George Somlo, MD, Leslie Popplewell, M.D., R. Spielberger, M.D., Neil Martin Kogut, MD, Chatchada Karanes, MD, Christopher Ruel, Paul Frankel, Eunicia Reburiano, Margret O'Donnell, MD, Stephen Forman

Blood (2010) 116 (21): 2399.

https://doi.org/10.1182/blood.V116.21.2399.2399

Published: 2010

Journal Articles

Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma.

Sahebi Firoozeh, MD, Jeffery R. Schriber, M.D., Ricardo Spielberger, M.D., Ji-Lian Cai, M.D., Neil Martin Kogut, M.D., Peter M. Falk, M.D., Pablo Miguel Parker, M.D., Amrita Krishnan, M.D., Leslie Popplewell, M.D., Chatchada Karanes, M.D., Dajun Qian, PhD., Stephen J. Forman, M.D., George Somlo, M.D.

Blood (2007) 110 (11): 3030.

https://doi.org/10.1182/blood.V110.11.3030.3030

Published: 2007

Journal Articles

The Impact of Disease Status on the Outcome of High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Peripheral T-Cell Lymphoma (PTCL).

Auayporn P. Nademanee, MD, Jasmine M. Zain, M.D., Joycelynne Palmer, Ph.D., Nicole Tsai, M.S., M.P.H., Neil Martin Kogut, M.D., Amrita Krishnan, M.D., Leslie Popplewell, M.D., Roberto Rodriguez, M.D., Eileen Patricia Smith, M.D., Stephen J. Forman, M.D.

Blood (2006) 108 (11): 3060.

https://doi.org/10.1182/blood.V108.11.3060.3060

Published: 2006

NARROW

PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib

Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation

Analysis of Risk Factors and Outcome for Extramedullary Relapses Post Allogeneic Stem Cell Transplantation for Myeloma.

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous Peripheral Stem Cell Transplant (PSCT) In Patients with Multiple Myeloma. Results of a Phase II Prospective Study

Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma.

The Impact of Disease Status on the Outcome of High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Peripheral T-Cell Lymphoma (PTCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only